Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EPS watch

EPS watch

Company 3Q07 EPS est 3Q07 EPS actual Outcome Growth from 3Q06 10/26 cls Wk chg % chg Mcap chg 10/26 Mcap
Affymetrix (AFFX) $0.06 $0.12 Beat by $0.06 NA $25.73 -$1.61 -6% -$110.1 $1,758.8
The microarray company posted a loss per share of $0.06 in 3Q06. Second quarter revenues were up 12% to $95M from $84.7M in 2Q06.
Amgen (AMGN) $1.03 $1.08 Beat by $0.05 4% $57.18 $1.23 2% $1,335.8 $62,097.5
3Q07 revenues were flat at $3.6B, while sales edged up 1% to $3.52B from $3.5B in 3Q06. The 2007 sales also reflect a positive foreign currency impact. 3Q07 sales of Aranesp for anemia were $818M, down 23% from $1.07B in 3Q06 and off by 14% from $949M in 2Q07. The decrease was primarily driven by label and reimbursement changes in the U.S. for all erythropoiesis-stimulating agents. First-generation EPO drug Epogen had 3Q07 sales of $602M, off 5% from $633M in the same period last year and down 4% from $624M in 2Q07. AMGN said the decrease was due to a decline

Read the full 1751 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers